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Abstract 
Background: Increased bone resorption and new bone information are two characteris-
tics of ankylosing spondylitis (AS). Much evidence has shown that carbonic anhydrase 
inhibitors can restrain bone resorption. We had detected increased expression of carbonic 
anhydrase I (CA1) in synovium of patients with AS. This study aimed to evaluate the 
effectiveness and safety of methazolamide, an anti-carbonic anhydrase drug, for treating 
patients with AS.  
Methods: Two patients, called as S and L, were diagnosed with active AS based on 
BASDAI and BASFI assessments, radiographic data and other clinical indices. They took 
methazolamide tablets at a dose of 25 mg twice every day.  
Results: Patient S's BASDAI score fell from 5.4 to 4.4, while patient L's BASDAI fell from 
2.4 to 2. Patient S's BASFI score change from 2.7 to 2.9, while patient L's BASFI score fell 
from 1.2 to 0.2. The ESR values of patient S were considerably reduced, while the ESR 
value of patient L remained unchanged and in the normal range. The calcium concentra-
tion of patient S decreased from 3.05 mmol/L to 2.39 mmol/L. The CT evidence indicates 
that the articular surfaces of the erosive sacroiliac joints became clearer and the area of 
the calcium deposits began decreased. No significant systemic side effects were observed 
in either patient.  
Conclusions: The above results indicate that methazolamide was effective for active AS. 
Methazolamide may improve AS symptoms by inhibiting carbonic anhydrase activity 
during the processes of bone reporption and new bone formation. 
Key words: ankylosing spondylitis (AS); carbonic anhydrase I (CA1); methazolamide; bone re-
porption; new bone formation 
Introduction 
Ankylosing  spondylitis  (AS)  is  a  chronic  in-
flammatory  rheumatic  disease  with  a  prevalence  of 
0.5–1.9% (1). Spinal inflammation, the hallmark of AS, 
causes  pain  and  stiffness  that  leads  to  progressive 
spinal deformity and fusion (1). The disease usually 
takes a chronic course that is characterized by bone 
resorption and new bone formation with syndesmo-
phytes and ankylosis (1). 
The  conventional  treatment  for  AS  is  mainly 
based  on  non-steroidal  anti-inflammatory  drugs 
(NSAIDs)  and  disease  modifying  anti-rheumatic 
drugs (DMARDs). Because NSAIDs such as celecoxib 
Ivyspring  
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have a rapid effect on inflammatory symptoms, these 
drugs are the most commonly used class of medica-
tion in treating the pain and stiffness associated with 
spondyloarthritis. In severe cases of AS, NSAIDs may 
only be partially effective or the side effects may be 
too severe to continue their use. In this case, a doctor 
may prescribe DMARDs such as sulfasalazine to re-
lieve severe symptoms of the disease (2-4). Currently, 
tumor  necrosis  factor  alpha  (TNF-a)  blockers  are 
recommended  for  AS  patients  with  insufficient  im-
provement under conventional treatment. All three of 
the  well-known  TNF  alpha  inhibitors  (infliximab, 
adalimumab and etanercept) have been shown to be 
highly effective at treating not only the arthritis of the 
joints but also the spinal arthritis associated with AS 
(5). Despite the diversity of conventional treatments 
available  for  the  treatment  of  AS,  no  optimal  treat-
ment plan has emerged to date (6). The current drugs 
are also used for rheumatoid arthritis (RA), juvenile 
RA,  psoriatic  arthritis  and  lupus  (7).  NSAIDs, 
DMARDs  and  TNF  alpha  inhibitors  control  AS 
symptoms  by  inducing  an  anti-inflammatory  re-
sponse. These drugs do not seem to have much in-
fluence on bone resorption and new bone formation 
in AS (8). For patients with AS, the future of success-
ful  treatment  lies  in  the  development  of  new  phar-
macological  interventions  capable  of  altering  the 
fundamental disease course. 
Recently, we applied a proteomics approach to 
identifying novel AS-specific proteins by comparing 
the expression profiles of synovial membranes from 
patients with AS, patients with rheumatoid arthritis 
(RA), and patients with osteoarthritis (OA). Proteins 
extracted from synovial tissues were separated by 2-D 
electrophoresis,  and  the  proteins  with  significantly 
higher expression in the AS samples were subjected to 
MALDI-TOF/TOF-MS  analysis.  The  proteomics  ap-
proach revealed significantly increased expression of 
carbonic  anhydrase  I  (CA1)  in  the  synovial  mem-
branes  of  patients  with  AS.  Immunohistochemistry 
and  western  blotting  analysis  confirmed  the  above 
findings.  ELISA  detected  a  higher  level  of  CA1  in 
synovial fluids from patients with AS than in the RA 
and  OA  samples  (9).  In  vitro  experiments  by  other 
groups indicated that CA1 catalyzes the generation of 
HCO3– through hydration  of CO2, which then com-
bines with Ca2+ to form a CaCO3 precipitate (10, 11). 
The formation of calcium salt crystals is an essential 
step  during  ossification.  Over-expression  of  CA1  in 
the synovium of AS patients may promote improper 
calcification  during  new  bone  formation,  an  im-
portant feature of AS. Thus, we suggested that car-
bonic anhydrase inhibitors such as acetazolamide and 
methazolamide could be effective treatments for AS.  
Methazolamide,  a  sulfonamide  derivative,  has 
been used to treat glaucoma for many years and is 
approved by the US FDA and China FDA. As a car-
bonic  anhydrase  inhibitor,  methazolamide  reduces 
the rate of fluid formation in the inner eye, presuma-
bly  by  slowing  the  formation  of  bicarbonate  ions, 
which causes a subsequent reduction in sodium and 
fluid transport (12). Much evidence has shown that 
carbonic  anhydrase  inhibitors  can  restrain  bone  re-
sorption (13-15). In the current study, we treated AS 
with methazolamide. We enrolled two patients with 
AS at the active stage in which new bone formation 
and bone resorption are occurring. Our goal was to 
assess the effectiveness and safety of methazolamide 
in patients with AS.  
METHODS  
Two patients, referred to as patient S and patient 
L,  were  enrolled  in  this  study.  The  study  was  ap-
proved  by  The  Ethics  Committee  of  Shandong 
Academy  of  Medical  Sciences.  Their  symptoms  ful-
filled the modified New York criteria for AS (16). They 
had histories of AS for 12 years and 3 years, respec-
tively.  The  patients  were  substantially  impaired  by 
back pain and spinal immobility. Physical examina-
tion  revealed  the  heart,  lungs  and  abdomen  to  be 
normal. Their eyes were normal without acute ante-
rior uveitis. Routine laboratory tests were within the 
normal  range  except  for  erythrocyte  sedimentation 
rate (ESR) in patient S. The ESRs of patient S and L 
were 36 mm/h and 12 mm/h (reference: 0-20 mm/h), 
respectively.  Analyses  to  detect  RF  and  anti-cyclic 
citrullinated peptide (anti-CCP) antibodies were both 
negative. The calcium concentration of patient S was 
3.05  mmol/L,  which  is  higher  than  normal  range 
(2.1-2.7 mmol/L). We measured disease activity using 
the Bath AS disease activity index (BASDAI), which is 
a questionnaire that assesses fatigue; neck, back and 
hip pain; peripheral joint pain and swelling; discom-
fort; and severity and duration of morning stiffness 
(17, 18). The BASDAI consists of a 1 through 10 scale 
(1 being no problem and 10 being the worst problem) 
that is used to assess the five major symptoms of AS. 
The  resulting  0  to  50  score  is  divided  by  the  five 
symptoms to give a final 0 – 10 BASDAI score. The 
BASDAI scores of patients S and L were 5.4 and 2.4, 
respectively. We also measured physical function of 
the  two  patients  using  BASFI  (Bath  ankylosing 
spondylitis functional index). The BASFI is a physical 
function questionnaire that evaluates dressing, bend-
ing, mobility, standing, stairs and full-day activities 
(19). The higher the BASFI score, the more severely 
the patient’s functioning is limited by their AS (1 be-
ing no problem and 10 being the worst problem). The Int. J. Med. Sci. 2011, 8 
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BASFI  scores  of  patients  S  and  L  were  2.7  and 1.2, 
respectively. We examined sacroiliac joints of the pa-
tients  with  computed  tomography  (CT)  and  plain 
x-ray  film.  The  results  revealed  bilateral  sacroiliitis 
with sclerosis and narrowing of the sacroiliac joints. 
One sacroiliac joint of patient S became bony fusion. 
The articular surfaces were blurred and seemed ser-
rated. Small erosions were observed at the corners of 
the  vertebral  bodies  in  the  spine,  indicative  of  ear-
ly-stage spondylitis. The above observation indicates 
that patients S and L had active AS at stage II, based 
on the protocol of Braun et al. (20). Table 1 summa-
rizes  the  information  regarding  the  two  patients. 
These two patients had previously had unsatisfactory 
therapy with at  least one  NSAID. The patients  had 
also been treated with DMARDs such as sulfasalazine 
and methotrexate. These therapies had been discon-
tinued  at  least  six  months  before  the  first  use  of 
methazolamide.  
This study was designed to examine efficacy and 
safety  of  oral  methazolamide  over  a  period  of  12 
weeks.  The  patients  took  a  25-mg  methazolamide 
tablet  twice  every  day.  The  data  collected  every 
month  included  the  BASDAI,  the  BASFI,  ESR,  im-
munoglobulin A, immunoglobulin G, immunoglobu-
lin M and calcium ion concentration. At the end of the 
treatment,  sacroiliac  joints  of  the  patients  were  ex-
amined with CT. 
Written informed consent was obtained from the 
patient for publication of this case report and any ac-
companying images. A copy of the written consent is 
available  for  review  by  the  Editor-in-Chief  of  this 
journal.  
 
Table 1. Baseline characteristics of the patients with AS 
pa-
tients 
gen-
der 
age(year
s) 
disease 
histo-
ry(years) 
radio-
graphic 
grade 
BASDA
1 
BASF
1 
S  man  28  12  stage II  5.4  2.7 
L  man  39  3  stage II  2.4  1.2 
 
 
RESULTS 
After 12 weeks of therapy with methazolamide, 
patients S and L showed obvious signs of improve-
ment as assessed by the BASDAI and BASFI. The total 
score BASDAI of patient S fell from 5.4 to 4.4, whereas 
the BASDAI of patient L fell from 2.4 to 1 for the first 
months, although the BASDAI rebounded to 2 at the 
third  month  following  the  treatment.  Obvious  im-
provements  in  fatigue,  morning  stiffness  and  total 
back pain were observed in the two patients. How-
ever, symptoms of peripheral joint pain and localized 
tenderness turned to more serious for patient L at the 
third  month  following  the  treatment.  The  physical 
functioning  of  the  two  patients  also  showed  im-
provement. The BASFI of patient S changed from 2.7 
to 2.9, while that of patient L fell from 1.2 to 0.2. Fig-
ure 1 and Figure 2 summarize the above results. Both 
patients  increased  their  physical  exercise  from  the 
second  month  of  the  treatment,  when  they  got  im-
provement with the disease. The ESR value of patient 
S was considerably reduced, while the value of pa-
tient L did not change and remained in the normal 
range.  The  IgM  level  of  patient  S  declined  signifi-
cantly  from  2.32  g/L  to  1.86  g/L  after  3  months’ 
treatment. The decline was especially improved at the 
first month following the treatment. The level of IgM 
of patient L did not change significantly and remained 
in the normal range after the treatment. The IgG levels 
and the IgA levels were increased for the two patients, 
although IgG level and the IgA level was considerably 
declined at the first month of the treatment for patient 
S. In addition, the calcium concentration of patient S 
fell from 3.05 mmol/L to 2.39 mmol/L, while the level 
of patient L remained in the normal range. Figure 3 
summarizes the above results. 
 
 
 
 
Figure 1. Measuring total scores of BASDAI (A) and BASFI (B) 
of AS patients with treatment of methazolamide. Int. J. Med. Sci. 2011, 8 
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Figure 2. Measuring each index of BASDAI and BASFI of AS patients with treatment of methazolamide. A and B show BASDAI 
levels of patient S and L, respectively. 1 represents fatigue, 2 spinal pain, 3 peripheral joint pain and swelling, 4 areas of 
localized tenderness, 5 severities and duration of morning stiffness. C and D show BASFI levels of patient S and L, respec-
tively. 1 represents putting on your socks or tights without help or aids, 2 bending from the waist to pick up a pen from the 
floor without aid, 3 reaching up to a high shelf without help or aids, 4 getting up from an armless chair without your hands 
or any other help, 5 getting up off the floor without help from lying on your back, 6 standing unsupported for 10 minutes 
without discomfort, 7 climbing 12-15 steps without using a handrail or walking aid, 8 looking over your shoulder without 
turning your body, 9 doing physically demanding activities, 10 doing a full day’s activities whether it be at home or at work. Int. J. Med. Sci. 2011, 8 
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Figure 3. Measuring ESR (A), IgG (B), IgA (C) and IgM (D) levels of AS patients with treatment of methazolamide. 
 
Figure 4. CT results of sacroiliac joints of patient S (1) and patient L (2) before (A) and after (B) the treatment of 
methazolamide. The evidence indicates that the articular surfaces of the erosive sacroiliac joints became clearer and the 
area of the calcium deposits began decreased. Int. J. Med. Sci. 2011, 8 
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Sacroiliac joints  of the patients  were examined 
with  CT  after  the  12  week’s  treatment.  Compared 
with the observation prior to the treatment, the artic-
ular surfaces  of the  joints became clearer and more 
distinct than before. The areas of the radioactive ma-
terial became decreased, indicating increased uptake 
of calcium deposits in the tissues. The above observa-
tion revealed that sacroiliitis, bony erosion and bone 
formation, hall marks of AS, got improvement during 
the  treatment  with  methazolamide.  Figure  4  shows 
the CT results.  
Significant systemic side effects such as kidney 
stones, depression, diarrhea and blood abnormalities 
were not observed in the two patients. Although la-
boratory  tests  showed  that  protein  concentrations 
increased from 0 to 0.15 g/L in the urea of patients S 
and L, this value is still within the normal range. The 
above  results  indicate  that  methazolamide  was 
well-tolerated by the patients after 12 weeks of treat-
ment. 
DISCUSSIONS 
In this study, two patients with active AS expe-
rienced  improvements  in  fatigue,  spinal  pain,  joint 
pain and morning stiffness following the treatment of 
methazolamide. BASDAI and BASFI assessments in-
dicated  that  they  improved  with  respect  to  disease 
activity  and  physical  functioning.  In  addition,  ESR 
and IgM levels markedly declined in one of the pa-
tients, indicating improvements in inflammation and 
disease activity. Furthermore, CT evidence indicated 
that  the  articular  surfaces  of  the  erosive  sacroiliac 
joints became clearer and the area of the calcium de-
posits began decreased, indicating the improvement 
of  sacroiliitis  with  the  two  patients.  These  results 
demonstrate  that  methazolamide  might  be  effective 
for treating patients with AS. On the other hand, the 
levels of IgG and IgA were increased in the two pa-
tients, although the levels were significantly declined 
in patient S at the first month following the treatment. 
We  cannot  explain  this  alternation  of  IgG  and  IgA 
levels. Mäki-Ikola et al reported that there is no clear 
correlation  between  the  disease  activity  and  occur-
rence of IgG and IgA in AS patients (21).  
AS is characterized by ossification of the spinal 
joints  and  ligaments.  Our  previous  study  demon-
strated that over-expression of CA1 in the synovium 
of AS patients may stimulate ossification by acceler-
ating CaCO3 precipitation. Methazolamide belongs to 
the  class  of  medications  called  carbonic  anhydrase 
inhibitors.  In  this  study,  we  found  that  methazola-
mide improved the symptom of the patients by global 
assessment.  Thus,  we  suggest  that  treatment  with 
methazolamide  might  restrain  the  process  of  new 
bone formation of AS by inhibiting CaCO3 precipita-
tion.  
Although  no  previous  reports  had  suggested 
that methazolamide might be useful for treating AS, 
evidence has shown that carbonic anhydrase inhibi-
tors can restrain bone resorption. Pierce et al. demon-
strated  a  functional  role  for  carbonic  anhydrase  in 
hormone-stimulated  bone  resorption  (13).  In  an  in 
vitro neonatal mouse calvarial culture system, Hall et 
al. found that carbonic anhydrase activity enhanced 
prostaglandin  E2's  stimulation  of  bone  resorption, 
indicating  that  carbonic  anhydrase  is  a  necessary 
component of the osteoclastic bone resorptive mech-
anism (14). Two years later, that group found that the 
carbonic anhydrase inhibitor acetazolamide inhibited 
bone resorption (15). Nolan et al. found that carbonic 
anhydrase inhibitors, including cetazolamide, ethox-
zolamide,  methazolamide  and  dichlorphenamide, 
reduced paw edema and attenuated the deterioration 
of the joints of rats with adjuvant arthritis. They sug-
gested that the carbonic anhydrase inhibitors combat 
arthritis  by  inhibiting  bone  resorption  (22).  The  in-
creased bone resorption is a characteristic of AS (23, 
24). Thus, we suggest that treatment with methazo-
lamide might also interfere with process of bone re-
sorption of AS. The bone mineral density of patients 
with AS is reduced (25, 26). The calcium concentration 
of patient S fell from 3.05 mmol/L to 2.39 mmol/L 
after the treatment, supporting the view that metha-
zolamide treatment may interfere with bone resorp-
tion in AS.  
We report a treatment of active AS with metha-
zolamide. The previous studies reported that metha-
zolamide as the carbonic anhydrase inhibitor can re-
strain  bone  resportion  and  stimulate  new  bone  for-
mation. This finding contributes to our understanding 
of the causes of AS, and it suggests a potential future 
for  this  drug  in  the  clinical  therapy.  Nevertheless, 
methazolamide is a treatment option that should be 
explored  in  the  near  future.  A  larger  pilot  study 
would be important to reproduce these findings. 
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